

ONE-PAGE CURRICULUM VITAE

Full Name:	MESSAS	Emmanuel	
Professional Mailing Address: emmanuel.messas@egp.aphp.fr			
Hôpital Européen Georges Pompidou, APHP-Centre, 20 rue leblanc 75015 Paris			
City: Paris	State/Province: N/A	Country: France	Zip/Postal Code:75015
Academic Qualifications:			
Degree and/or Certification	Date (YYYY)	Institution	
BA in Mathematics with Honors	1987-88	Academy of Paris, Paris, France	
MD in Medecine	1988-94	Lariboisiere Medical School, Paris, France	
PhD in Medical Bioengineering	2006	Institute of Science and Medical Research	
Medical License Number : RPPS: 10003744793		State/Province : N/A	Country: France
Current Position at Study Site:			
Start Date	Title	Institution or Company	Country
2012-today	Professor of Medicine and Head of the Vascular unit and Ultrasound cardiovascular lab	HEGP, University Paris Descartes	France
Other/Previous Relevant Positions Including Academic Appointments:			
Start and End Dates	Title	Institution or Company	Country
2010-2012	Professor of Medicine, Cardio-Vascular Department,	HEGP, University Paris Descartes	France
2005-2010	Assistant professor (praticien hospitalier)	HEGP and Hôpital Necker Paris	France
2001-2004	Instructor in Medicine, Cardiology,	HEGP, Paris,	France.
1999-2001	Research Fellow in Medicine,	Massachusetts General Hospital and Harvard Medical School,	Boston
Brief Summary of Relevant Clinical Research Experience:			
<ul style="list-style-type: none"> ➤ 1999- 2001: Georges Lurcy Charitable & Educational Trust;French Ministry of Foreign Affairs, Harvard Club of France: Integrated Mechanism of Ischemic Mitral Regurgitation. (Co-Investigator) ➤ 2002-2005: R21 NIH Grand on Therapeutic Approaches to Ischemic Mitral Regurgitation Using Tissue Regeneration and more specifically, autologous skeletal myoblast implantation. (Co-Investigator) ➤ 2004-2006: Supplement R21 grand on human embryonic stem cell and ischemic mitral regurgitation ➤ 2004- 2009: ROI on new therapeutic approaches for ischemic mitral regurgitation (Co-Investigator) ➤ 2008-2010: Grand TecSAN-ANR (Agence Nationale pour la Recherche): Cardio-vascular application of ultrafastecho with Supersonic Shear imaging modalities. ➤ 2008-2013: Leducq. Transatlantic Network (Assistant Member): Mitral valve disease: From Gene to therapy. ➤ 18/10/2012: XALIA: Xarelto in Clinical condition practice compared to current standard therapy in patients with VTE. (PI) ➤ 11/01/2013: Xantus: Xarelto in prevention of stroke and non-CNS systemic embolism in patients with ACFA. (Sub-Investigator) ➤ 02/12/2013: EUCLID: Clopidogrel VS Ticagrelor on risk of cardiovascular death, MI and ischemic stroke in patients with PAD, Phase III, double-blind, randomized. (PI) ➤ 06/26/2013: APEX: Betrixaban vs lovenox in the prevention of VTE, Phase III, double-blind, randomized. (PI) ➤ 19/04/2013: AEGEAN: Therapeutic education and support program for Apixaban in non-valvular AF Phase IV (PI). ➤ 21/01/2014: COMPASS: Rivaroxaban (Xarelto) vs aspirin + pantoprazole in the prevention of cardiovascular events in patients with coronary artery disease or peripheral arterial disease (PI) ➤ 10.6.2014: Einstein Choice: Rivaroxaban (Xarelto) reduced dose (10mg), normal dose (20mg) vs aspirin (100mg) in the treatment of VTE in patients with DVT and / or PE (PI) ➤ 2014-2019: THEMIS: assessment of ticagrelor (Brilique) 90 mg 2x / day on the incidence of cardiovascular death, MI, or stroke in type 2 diabetic patients (PI) ➤ 2017/2018: ARYEL: a prospective registry of echographic loops (PI) ➤ 2017-2020: DETECTOR: dépistage des cancers liés au tabac par scanner faible dose et recherche de cellules tumorales circulantes (PI) ➤ 2018: COMPASS LTOLE (PI) ➤ 2018: REMOVE: REduced dose versus full-dose of direct oral anticoagulant after uNprovoked Venous thromboembolism (PI) ➤ 2019: Valvosoft: Prospective, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft Pulsed Cavitation Ultrasound Therapy (PCUT) (PI). 			
Signature:		Signature Date: 20/01/2020	
I will update and resubmit my one page CV if there are changes and particularly if there is any change in status which would adversely affect the assessment of my suitability to conduct/participate in clinical studies.			

ONE-PAGE CURRICULUM VITAE